VARIBAR THIN LIQUID
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VARIBAR THIN LIQUID (VARIBAR THIN LIQUID).
VARIBAR THIN LIQUID (barium sulfate) is a radiopaque contrast agent. Its mechanism involves coating the mucosal surface of the gastrointestinal tract, attenuating X-rays, and providing radiographic visualization of anatomical structures.
| Metabolism | Barium sulfate is not absorbed systemically; it is excreted unchanged in feces. |
| Excretion | VARIBAR THIN LIQUID (barium sulfate) is not absorbed systemically. It is eliminated entirely via the gastrointestinal tract, with >99% excreted unchanged in feces within 24-72 hours. Renal or biliary elimination is negligible (<0.01%). |
| Half-life | Not applicable; the compound is not absorbed and does not exhibit a systemic half-life. Gastrointestinal transit time is approximately 1-3 hours for small bowel follow-through, with colonic elimination occurring over 24-72 hours. |
| Protein binding | 0% (barium sulfate is insoluble and not absorbed; no protein binding occurs). |
| Volume of Distribution | 0 L/kg (confined to gastrointestinal lumen; no systemic distribution). |
| Bioavailability | Oral: 0% (barium sulfate is not absorbed from the intact gastrointestinal tract). |
| Onset of Action | Oral administration: Radiopacification of the upper gastrointestinal tract begins immediately upon ingestion, with esophageal visualization within seconds and gastric mucosal coating within 1-2 minutes. Small bowel opacification occurs within 15-30 minutes. |
| Duration of Action | Oral administration: Adequate mucosal coating persists for 30-60 minutes in the stomach and proximal small bowel. Colonic opacification, if used for contrast enema, lasts 10-30 minutes before dilution occurs. Complete elimination from the bowel occurs within 24-72 hours. |
| Molecular Weight | 233.39 |
Oral administration: 30-100 mL of a 30% w/v barium sulfate suspension, given as a single dose for upper GI studies; adjust volume and concentration based on imaging technique and patient anatomy.
| Dosage form | FOR SUSPENSION |
| Renal impairment | No dose adjustment required; barium sulfate is not absorbed systemically and is excreted unchanged in feces. |
| Liver impairment | No dose adjustment required; drug is not metabolized by the liver. |
| Pediatric use | Weight-based: For upper GI series, 5-10 mL/kg of a 30% w/v suspension orally, up to a maximum of 100 mL; for barium enema, 15-20 mL/kg of a 30% w/v suspension per rectum. |
| Geriatric use | Use with caution due to increased risk of aspiration and constipation; consider lower volumes (e.g., 30-60 mL) and monitor for bowel obstruction. |
| 1st trimester | Barium sulfate is not absorbed systemically; thus, no fetal risk is expected. However, radiation exposure from fluoroscopy should be considered. |
| 2nd trimester | Same as T1. No known teratogenic effects from the contrast agent itself. |
| 3rd trimester | Same as T1. Near term, consider potential for neonatal hypothyroidism if iodine-containing agents are used; VARIBAR THIN LIQUID is barium sulfate, not iodine-based, so risk is negligible. |
Clinical note
Comprehensive clinical and safety monograph for VARIBAR THIN LIQUID (VARIBAR THIN LIQUID).
| Placental transfer | Barium sulfate is not absorbed from the GI tract; thus, no significant placental transfer occurs. Any trace absorption is minimal. |
| Breastfeeding | Barium sulfate is not absorbed orally; therefore, negligible transfer into breast milk. Considered compatible with breastfeeding. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Suspected or known gastrointestinal perforationKnown hypersensitivity to barium sulfateIntestinal obstructionTracheoesophageal fistula
| Precautions | Risk of aspiration pneumonitis if aspirated into lungs, Intestinal perforation: may cause peritonitis or granuloma formation, Hypersensitivity reactions: rare but possible, Impaired GI motility: risk of impaction or obstruction, Use with caution in patients with known or suspected bowel obstruction or perforation |
| Food/Dietary | Avoid eating or drinking anything other than small sips of water for 4-6 hours before the procedure to ensure an empty stomach. No specific food interactions during use, but concurrent administration with medications that alter GI motility may affect transit time. |
Loading safety data…
| Lactation Rating | Safe |
| Teratogenic Risk | Barium sulfate is not absorbed systemically and is considered to have negligible teratogenic risk. No fetal risks have been reported with oral or rectal administration during any trimester due to lack of systemic exposure. |
| Fetal Monitoring | No specific maternal or fetal monitoring is required for Varibar Thin Liquid due to lack of systemic absorption. Standard monitoring for aspiration risk during swallowing studies may apply. |
| Fertility Effects | No effects on fertility have been reported or are expected due to lack of systemic absorption. |
| Clinical Pearls | Varibar Thin Liquid is a barium sulfate suspension for oral use during fluoroscopic GI exams. Its low viscosity facilitates rapid coating of mucosal surfaces, ideal for swallowing assessments. For patients with suspected aspiration, use a careful, graded administration starting with minimal volumes. Monitor for barium aspiration, which can cause granulomatous inflammation. Ensure adequate hydration post-procedure to prevent constipation or fecal impaction, especially in elderly or debilitated patients. |
| Patient Advice | Take only as directed by your healthcare provider; do not mix with other substances unless instructed. · Drink plenty of fluids after the procedure to help pass the barium from your body. · Inform your doctor if you have a history of intestinal blockage, perforation, or severe constipation. · Your stools may appear white or chalky for a few days after the exam; this is normal. · Contact your doctor if you experience severe abdominal pain, inability to pass stool, or breathing difficulty after the test. |